GI-Pro snap by Mānuka Performance
GI-pro snaps are a formulation that contains Mānuka honey (XX%), Rewrewa honey (XX%) and Probiotics (Ganeden BC30 - Bacillus coagulans GBI-30, 6086). Ganeden BC30 has been approved for high level health claims for digestive health. Australian and New Zealand food regulators publish probiotic claims (nutraceuticalbusinessreview.com)
GI-pro meet the following criteria of a dietary supplement in the Dietary Supplements Regulations (1986):
Meaning of dietary supplement
(1)In these regulations, dietary supplement means something to which subclauses (2) to (6) apply.
(2)It is an amino acid, edible substance, herb, mineral, synthetic nutrient, or vitamin.
(3)It is sold by itself or in a mixture.
(4)It is sold in a controlled dosage form as a liquid, powder, or tablet (which might be described on the label as a cachet, capsule, lozenge, or pastille instead of as a tablet).
(5)It is intended to be ingested orally.
(6)It is intended to supplement the amount of the amino acid, edible substance, herb, mineral, synthetic nutrient, or vitamin normally derived from food.
Labelling Requirements
Every package and container containing a dietary supplement shall, unless otherwise provided in these regulations, bear a label that includes the following:
- the common name of the dietary supplement, or a description (other than the brand name of the dietary supplement) sufficient to indicate the true nature of the dietary supplement, or a description of the dietary supplement including the common names of its principal ingredients:
While the effects of GI-pro have not been researched, human and in vitro trials have been conducted with Bacillus coagulans (the probiotic in the GI-pro snap formulation).
Clinical trials of relevance to the current manuka honey and Ganeden BC30 formulation are:
Anaya-Loyola, M. A., Enciso-Moreno, J. A., López-Ramos, J. E., García-Marín, G., Álvarez, M. Y. O., Vega-García, A. M., ... & Pérez-Ramírez, I. F. (2019). Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Food Research International, 125, 108567.
Benson, K. F., Redman, K. A., Carter, S. G., Keller, D., Farmer, S., Endres, J. R., & Jensen, G. S. (2012). Probiotic metabolites from Bacillus coagulans GanedenBC30TM support maturation of antigen-presenting cells in vitro. World Journal of Gastroenterology: WJG, 18(16), 1875.
Endres, J. R., Clewell, A., Jade, K. A., Farber, T., Hauswirth, J., & Schauss, A. G. (2009). Safety assessment of a proprietary preparation of a novel Probiotic, Bacillus coagulans, as a food ingredient. Food and Chemical Toxicology, 47(6), 1231-1238.
Gepner, Y., Hoffman, J. R., Shemesh, E., Stout, J. R., Church, D. D., Varanoske, A. N., ... & Ostfeld, I. (2017). Combined effect of Bacillus coagulans GBI-30, 6086 and HMB supplementation on muscle integrity and cytokine response during intense military training. Journal of Applied Physiology, 123(1), 11-18.
Jäger, R., Shields, K. A., Lowery, R. P., De Souza, E. O., Partl, J. M., Hollmer, C., ... & Wilson, J. M. (2016). Probiotic Bacillus coagulans GBI-30, 6086 reduces exercise-induced muscle damage and increases recovery. PeerJ, 4, e2276.
Jensen, G. S., Benson, K. F., Carter, S. G., & Endres, J. R. (2010). GanedenBC 30™ cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC immunology, 11, 1-14.
Jensen, G. S., Cash, H. A., Farmer, S., & Keller, D. (2017). Inactivated probiotic Bacillus coagulans GBI-30 induces complex immune activating, anti-inflammatory, and regenerative markers in vitro. Journal of inflammation research, 107-117.
Kalman, D., & Hewlings, S. (2018). Inactivated probiotic Bacillus coagulans GBI-30 demonstrates Immunosupportive properties in healthy adults following stressful exercise. J Probiotics and Health, 6.
Kimmel, M., Keller, D., Farmer, S., & Warrino, D. E. (2010). A controlled clinical trial to evaluate the effect of GanedenBC (30) on immunological markers. Methods and Findings in Experimental and Clinical Pharmacology, 32(2), 129-132.
Selbovitz, M., Keller, Farmer, & Bray. (2012). A review of probiotics studies in HIV research suggests improved immunological presentation and preservation of viral host restrictive factors of TH17 in HIV patients. Retrovirology, 9 (Suppl 1), P22.